Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CTLA-4 monoclonal antibody-IL-15/IL-15Ra fusion protein JK08

A recombinant fusion protein consisting of a human monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) fused to the immunostimulatory cytokine interleukin-15 (IL-15) cross-linked with the sushi domain of IL-15 receptor alpha (IL-15Ra), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of anti-CTLA-4 monoclonal antibody-IL-15/IL-15Ra fusion protein JK08, the monoclonal antibody domain targets and binds to CTLA-4 expressed on T cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. The IL-15/IL-15Ra complex targets and binds to CD8+ T and natural killer (NK) cells, thereby increasing their activation and proliferation. Altogether, this leads to an inhibition of regulatory T-cell (Tregs)-mediated immunosuppression, induces antibody-dependent cellular cytotoxicity (ADCC), increases memory T cells and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.
Synonym:fusion protein JK08
Code name:JK 08
JK-08
JK08
Search NCI's Drug Dictionary